Should I buy or sell Fusion Pharmaceuticals stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 13 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FUSN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FUSN, but not buy additional shares or sell existing shares. View FUSN analyst ratings or view top-rated stocks .

What is Fusion Pharmaceuticals' stock price target for 2024?

14 brokerages have issued 1 year price objectives for Fusion Pharmaceuticals' stock. Their FUSN share price targets range from $15.00 to $24.00. On average, they anticipate the company's stock price to reach $20.25 in the next twelve months. This suggests that the stock has a possible downside of 4.7%. View analysts price targets for FUSN or view top-rated stocks among Wall Street analysts .

How have FUSN shares performed in 2024?

Fusion Pharmaceuticals' stock was trading at $9.61 on January 1st, 2024. Since then, FUSN shares have increased by 121.1% and is now trading at $21.25. View the best growth stocks for 2024 here .

When is Fusion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FUSN earnings forecast .

How were Fusion Pharmaceuticals' earnings last quarter?

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.05. Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative trailing twelve-month return on equity of 46.59%.

What ETFs hold Fusion Pharmaceuticals' stock?

ETFs with the largest weight of Fusion Pharmaceuticals (NASDAQ:FUSN) stock in their portfolio include ProShares Merger ETF (MRGR) and IQ Merger Arbitrage ETF (MNA) . Fidelity Disruptive Medicine ETF (FMED) .

What other stocks do shareholders of Fusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK) , U.S. Xpress Enterprises (USX) , Camping World (CWH) , DocuSign (DOCU) , Pfizer (PFE) , Pure Storage (PSTG) , CrowdStrike (CRWD) , Livongo Health (LVGO) , NVIDIA (NVDA) and OPKO Health (OPK) .

When did Fusion Pharmaceuticals IPO?

Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Fusion Pharmaceuticals?

Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FUSN

Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free FUSN Stock Alerts

$21.25

+0.01 (+0.05%)

(As of 05:17 PM ET)

Compare

Today's Range: $21.20
▼
$21.30
50-Day Range: $9.34
▼
$21.43
52-Week Range: $2.31
▼
$21.55

Volume: 329,188 shs
Average Volume: 2.06 million shs
Market Capitalization: $1.80 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.25

Get Fusion Pharmaceuticals alerts:

Fusion Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Hold
2.07 Rating Score
Upside/Downside: 4.7% Downside
$20.25 Price Target
Short Interest: Healthy
6.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.20
Based on 13 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.46) to ($1.69) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.71 out of 5 stars

Medical Sector

846th out of 919 stocks

Biotechnology Industry

18th out of 27 stocks

2.0

Analyst's Opinion

Consensus Rating
Fusion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 1 buy rating, 13 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Fusion Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
6.13% of the outstanding shares of Fusion Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Fusion Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fusion Pharmaceuticals has recently decreased by 34.34%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Fusion Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Fusion Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FUSN.

1.8

News and Social Media Coverage

News Sentiment
Fusion Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Fusion Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 18 people have searched for FUSN on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Fusion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fusion Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.75% of the stock of Fusion Pharmaceuticals is held by insiders.
Percentage Held by Institutions
72.85% of the stock of Fusion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Fusion Pharmaceuticals are expected to decrease in the coming year, from ($1.46) to ($1.69) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fusion Pharmaceuticals is -14.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fusion Pharmaceuticals is -14.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fusion Pharmaceuticals has a P/B Ratio of 6.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

FUSN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FUSN Stock News Headlines

April 17, 2024 | finance.yahoo.com

Fusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should Know

April 17, 2024 | msn.com

TD Cowen Downgrades Fusion Pharmaceuticals (FUSN)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 17, 2024 | americanbankingnews.com

Fusion Pharmaceuticals' (FUSN) Hold Rating Reaffirmed at TD Cowen

April 15, 2024 | americanbankingnews.com

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Receives Consensus Rating of "Hold" from Analysts

April 13, 2024 | americanbankingnews.com

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) to Post Q1 2024 Earnings of ($0.37) Per Share, Leerink Partnrs Forecasts

April 11, 2024 | finance.yahoo.com

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the company

April 9, 2024 | finance.yahoo.com

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | prnewswire.com

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024

April 3, 2024 | msn.com

Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio

March 28, 2024 | msn.com

What Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for Investors

March 26, 2024 | prnewswire.com

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN

March 20, 2024 | msn.com

FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023

March 20, 2024 | stockhouse.com

Kuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law Firm

March 20, 2024 | markets.businessinsider.com

Fusion Pharmaceuticals: Hold Rating Justified Amid Acquisition and Radiopharmaceutical Market Dynamics

March 20, 2024 | finance.yahoo.com

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates

March 20, 2024 | markets.businessinsider.com

Unveiling 11 Analyst Insights On Fusion Pharmaceuticals

March 19, 2024 | businesswire.com

FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN

March 19, 2024 | businesswire.com

March 19, 2024 | finance.yahoo.com

Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal

March 19, 2024 | finance.yahoo.com

Super Micro, XPeng, AstraZeneca: Trending tickers

March 19, 2024 | finance.yahoo.com

Fusion Rockets 97%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover

March 19, 2024 | financialpost.com

AstraZeneca to buy Canadian cancer treatment developer Fusion Pharmaceuticals

March 19, 2024 | proactiveinvestors.com

AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting

March 19, 2024 | investorplace.com

Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today?

March 19, 2024 | investorplace.com

Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today?

See More Headlines

Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:FUSN
CUSIP: N/A
CIK: 1805890
Web: fusionpharma.com
Phone: 289-799-0891
Fax: N/A
Employees: 101
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.25
High Stock Price Target: $24.00
Low Stock Price Target: $15.00
Potential Upside/Downside: -4.7%
Consensus Rating: Hold
Rating Score (0-4): 2.07
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-94,900,000.00
Net Margins: -4,136.55%
Pretax Margin: -4,550.77%
Return on Equity: -46.59%
Return on Assets: -35.34%

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 15.01
Quick Ratio: 15.01

Sales & Book Value

Annual Sales: $2.07 million
Price / Sales: 870.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.07 per share
Price / Book: 6.92

Miscellaneous

Outstanding Shares: 84,860,000
Free Float: 78,288,000
Market Cap: $1.80 billion
Optionable: Optionable
Beta: -0.72

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. John F. Valliant Ph.D. (Age 53)
Founder, CEO & Director
Comp: $911.34k
Dr. Christopher Paul Leamon Ph.D. (Age 58)
Chief Scientific Officer
Ms. Amanda Cray
Senior Director of Investor Relations & Corporate Communications
Ms. Maria D. Stahl (Age 53)
Chief Legal Officer
Mr. Eric S. Hoffman Ph.D. (Age 54)
Senior Vice President of Business Development
Dr. Cara Ferreira Ph.D.
Chief of Staff
Dr. Joanne Schindler
Executive Vice President of Medical Director & Clinical Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

FUSN Stock Analysis - Frequently Asked Questions

Should I buy or sell Fusion Pharmaceuticals stock right now?: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 13 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FUSN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FUSN, but not buy additional shares or sell existing shares.
View FUSN analyst ratings or view top-rated stocks.
What is Fusion Pharmaceuticals' stock price target for 2024?: 14 brokerages have issued 1 year price objectives for Fusion Pharmaceuticals' stock. Their FUSN share price targets range from $15.00 to $24.00. On average, they anticipate the company's stock price to reach $20.25 in the next twelve months. This suggests that the stock has a possible downside of 4.7%.
View analysts price targets for FUSN or view top-rated stocks among Wall Street analysts.
How have FUSN shares performed in 2024?: Fusion Pharmaceuticals' stock was trading at $9.61 on January 1st, 2024. Since then, FUSN shares have increased by 121.1% and is now trading at $21.25.
View the best growth stocks for 2024 here.
When is Fusion Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FUSN earnings forecast.
How were Fusion Pharmaceuticals' earnings last quarter?: Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.05. Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative trailing twelve-month return on equity of 46.59%.

What ETFs hold Fusion Pharmaceuticals' stock?: ETFs with the largest weight of Fusion Pharmaceuticals (NASDAQ:FUSN) stock in their portfolio include ProShares Merger ETF (MRGR) and IQ Merger Arbitrage ETF (MNA).Fidelity Disruptive Medicine ETF (FMED).
What other stocks do shareholders of Fusion Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK).
When did Fusion Pharmaceuticals IPO?: Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
How do I buy shares of Fusion Pharmaceuticals?: Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FUSN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis

Fusion Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

FUSN Stock Price History

FUSN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

FUSN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™